Sarah Gooding
Sarah Gooding
Weatherall Institute, University of Oxford
Verified email at - Homepage
Cited by
Cited by
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
S Gooding, N Ansari-Pour, F Towfic, M Ortiz EstÚvez, PP Chamberlain, ...
Blood, The Journal of the American Society of Hematology 137 (2), 232-237, 2021
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion‐dependent thalassaemia
SA Fisher, SJ Brunskill, C Doree, S Gooding, O Chowdhury, DJ Roberts
Cochrane Database of Systematic Reviews, 2013
Mycobacterium tuberculosis-Specific Cellular Immune Profiles Suggest Bacillary Persistence Decades after Spontaneous Cure in Untreated Tuberculosis
KA Millington, S Gooding, TSC Hinks, DJM Reynolds, A Lalvani
The Journal of infectious diseases 202 (11), 1685-16849, 2010
Oral deferiprone for iron chelation in people with thalassaemia
SA Fisher, SJ Brunskill, C Doree, O Chowdhury, S Gooding, DJ Roberts
Cochrane Database of Systematic Reviews, 2013
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3
SR Pasricha, PJ Lim, TL Duarte, C Casu, D Oosterhuis, ...
Nature communications 8 (1), 403, 2017
Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease
S Gooding, SWZ Olechnowicz, EV Morris, AE Armitage, J Arezes, J Frost, ...
Nature communications 10 (1), 4533, 2019
New approaches to targeting the bone marrow microenvironment in multiple myeloma
S Gooding, CM Edwards
Current opinion in pharmacology 28, 43-49, 2016
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice
S Gooding, O Chowdhury, T Hinks, L Richeldi, M Losi, K Ewer, ...
Journal of Infection 54 (3), e169-e174, 2007
Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders
C Anzilotti, AK Kienzler, E Lopez-Granados, S Gooding, B Davies, ...
Journal of Allergy and Clinical Immunology 136 (2), 487-490. e2, 2015
Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies
AO Khan, A Rodriguez-Romera, JS Reyat, AA Olijnik, M Colombo, ...
Cancer discovery 13 (2), 364-385, 2023
MicroRNA expression in chronic lymphocytic leukaemia
CH Lawrie, E Ballabio, OJ Dyar, M Jones, R Ventura, J Chi, D Tramonti, ...
British journal of haematology 147 (3), 398-402, 2009
Managing multiple myeloma in the over 70s: a review
AJ King, S Gooding, K Ramasamy
Maturitas 80 (2), 148-154, 2015
COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma
K Ramasamy, R Sadler, S Jeans, S Varghese, A Turner, J Larham, ...
British Journal of Haematology 196 (1), 95-98, 2022
Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment
SWZ Olechnowicz, MM Weivoda, ST Lwin, SK Leung, S Gooding, ...
Scientific reports 9 (1), 14189, 2019
Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect
TA Eyre, S Gooding, I Patel, N Moore, C Hatton, GP Collins
International journal of hematology 99, 798-800, 2014
Immune response to COVID‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
K Ramasamy, R Sadler, S Jeans, P Weeden, S Varghese, A Turner, ...
British Journal of Haematology 197 (3), 293-301, 2022
Double relapsed and/or refractory multiple myeloma: clinical outcomes and real world healthcare costs
S Gooding, IJ Lau, M Sheikh, P Roberts, J Wong, E Dickens, A Bullement, ...
PLoS One 10 (9), e0136207, 2015
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
N Ansari-Pour, M Samur, E Flynt, S Gooding, F Towfic, N Stong, ...
Blood, The Journal of the American Society of Hematology 141 (6), 620-633, 2023
Myeloma Genome Project Panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma
P Sudha, A Ahsan, C Ashby, T Kausar, A Khera, MH Kazeroun, CC Hsu, ...
Clinical Cancer Research 28 (13), 2854-2864, 2022
Multidimensional single cell analysis shows increased T/NK cell subsets in both blood and bone marrow of iberdomide (CC-220) treated relapsed/refractory multiple myeloma patients
M Amatangelo, O Van Oekelen, AH Rahman, A Lagana, S Gooding, ...
Blood 134, 1775, 2019
The system can't perform the operation now. Try again later.
Articles 1–20